| Open Document File Size: 72,45 KBShare Result on Facebook
City Kansas City / Wayne / City / / Company Merck & Co. Inc. / Turner White Communications Inc. / REMICADE Centocor Inc. / Teva Neuroscience Inc. / / Event Product Issues / / Facility Whitehouse Station / / IndustryTerm pharmaceutical company press releases / treatment of the signs and symptoms / prevention of herpes / / MedicalCondition dyskinesia / accidental injury / early Parkinson’s disease / troublesome dyskinesia / viral infection / flushing / headache / arthralgia / herpes zoster / shingles / leukopenia / idiopathic Parkinson’s disease / neutropenia / Crohn’s disease / nausea / dyskinesia / erythema / developed shingles / severely active Crohn’s disease / moderate-to-advanced disease / postherpetic neuralgia / advanced Parkinson’s disease / Infections / zoster / / MedicalTreatment biologic therapy / / Organization US Food and Drug Administration / / Person Tricia Faggioli / / / Position Hospital Physician / / Product AZILECT / REMICADE / response / / ProvinceOrState Pennsylvania / / URL www.turner-white.com / /
SocialTag |
Rx Update Drugs recently approved or pending approval AZILECT The US Food and Drug Administration (FDA) has given approval to Teva Neuroscience, Inc. (Kansas City, MO) to market Azilect (rasagiline) for the treatment o